<DOC>
	<DOCNO>NCT00871533</DOCNO>
	<brief_summary>The presence malignant cell lymph node critical parameter stag melanoma cancer patient . Assessment lymph node currently do histopathology alone . The long-term survival melanoma cancer patient Stage IB disease ( know lymph node involvement tumor great 2 cm ) low patient Stage IA ( know lymph node involvement tumor le 2 cm ) . Likewise , survival rate patient judge Stage II base histologically positive level-one lymph node often better high stage patient level-two lymph node involvement . These observation suggest micrometastases often present lymph node detectable histological assessment . The collection Sentinel Lymph Nodes ( SLN ) non SLN material outline proposal permit target exploratory study , without compromise patient 's diagnosis , specimens represent central engine immune response whose function context tumor progression largely unknown . With advent array new methodology utilize minimum material molecular cellular assessment , acquire 20 % general investigator anticipate use 5 % average SLN and/or non SLN tissue research purpose , may prove critical understanding impact nodal tumor involvement patient outcome survival .</brief_summary>
	<brief_title>Pilot Study IFN Î±2b Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Primary melanoma follow Breslow thickness stage less equal 2 mm Patients recent ( within 12 wks ) biopsy primary melanoma widely resect eligible study accord abovespecified criterion tumor thickness stage . Age 18 year old . Patients must document hemoglobin level 10g/dL high normal organ function test include BUN , Creatinine , liver enzyme panel include AST , ALT , Bilirubin . This drawn day consent , document previous visit within past 30 day Negative serum pregnancy test Subjects must provide write , informed consent prior study procedure : collection blood LN tissue specimens protocol . Serious illness , : cardiovascular disease ( uncontrolled congestive heart failure , hypertension , cardiac ischemia , myocardial infarction , severe cardiac arrhythmia ) , bleed disorder , autoimmune disease , severe obstructive restrictive pulmonary disease , active systemic infection , inflammatory bowel disorder , severe renal disease . Any significant psychiatric disease , medical intervention , condition , opinion Principal Investigator CoInvestigators , could prevent adequate informed consent compromise participation clinical trial . Active infection antibiotic within oneweek prior study . Systemic steroid immunosuppressive therapy administer 10 day within 4 week enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Biochemical Marker</keyword>
	<keyword>Biochemical Markers</keyword>
	<keyword>Biologic Marker</keyword>
	<keyword>Biologic Markers</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Clinical Marker</keyword>
	<keyword>Clinical Markers</keyword>
	<keyword>Immune Marker</keyword>
	<keyword>Immune Markers</keyword>
	<keyword>Immunologic Marker</keyword>
	<keyword>Immunologic Markers</keyword>
	<keyword>Laboratory Marker</keyword>
	<keyword>Laboratory Markers</keyword>
	<keyword>Marker , Biochemical</keyword>
	<keyword>Marker , Biological</keyword>
	<keyword>Marker , Clinical</keyword>
	<keyword>Marker , Immunologic</keyword>
	<keyword>Marker , Laboratory</keyword>
	<keyword>Marker , Serum</keyword>
	<keyword>Marker , Surrogate</keyword>
	<keyword>Markers , Biochemical</keyword>
	<keyword>Markers , Biological</keyword>
	<keyword>Markers , Clinical</keyword>
	<keyword>Markers , Immunologic</keyword>
	<keyword>Markers , Laboratory</keyword>
	<keyword>Markers , Serum</keyword>
	<keyword>Markers , Surrogate</keyword>
	<keyword>Markers , Viral</keyword>
	<keyword>Serum Marker</keyword>
	<keyword>Serum Markers</keyword>
	<keyword>Surrogate End Point</keyword>
	<keyword>Surrogate End Points</keyword>
	<keyword>Surrogate Endpoint</keyword>
	<keyword>Surrogate Endpoints</keyword>
	<keyword>Surrogate Marker</keyword>
	<keyword>Surrogate Markers</keyword>
	<keyword>Viral Marker</keyword>
	<keyword>Viral Markers</keyword>
</DOC>